Abstract

AbstractBackgroundThe on‐going ‘Remote Assessment of Disease and Relapse – Alzheimer’s Disease’ (RADAR‐AD, https://www.radar‐ad.org/) international study uses remote monitoring technologies (RMT’s) to continuously and objectively monitor functional decline in Alzheimer’s Disease (AD). Managing finances is an Instrumental Activity of Daily Living (IADL), usually measured via traditional pen‐paper methods and interviews. To simulate this IADL, we present the ‘Banking App’ and preliminary results from the RADAR‐AD study.MethodIn the app, users enter a PIN, an amount to withdraw and confirm all inputs, using a numpad on a tablet’s touchscreen that resembles an ATM (Figure 1) provided in eight translations. Metrics collected include the duration and correctness of each step (i.e. PIN, Amount and confirmation) and attempt as a whole. The 36 participants to date (Figure 2), from four European sites, performed neuropsychological tests (e.g., MMSE, Rey) and include 20 amyloid negative cognitively normal healthy controls (HC) and 16 amyloid positive, of which 6 cognitively normal preclinical AD (PreAD), 6 cognitively impaired prodromal AD (ProAD) and 4 Mild to Moderate AD (MildAD). Clinicians provided a PIN and an amount to enter from a bill in a controlled lab setting. Statistical analysis included One Way ANOVA, t‐test and Mann‐Whitney between groups in pairs and Pearson correlation.ResultANOVA showed significance between groups mainly in amount and confirmation durations (p=0.010, p=0.002), leading to t‐test in group pairs (Figures 3 in numbers, visualized in Figure 4), showing increasing durations for more cognitively impaired groups and significant difference between amount and confirmation durations between HC and MildAD (p=0.011, p=0.002). Pearson correlations and heat map (Figure 5) relate app metrics and neuropsychological tests (e.g., MMSE, ADCS with correct amount, p=0.005, and confirmation duration, p=0.001).ConclusionPreliminary findings highlight that managing finances via an app relates to cognitive assessment, further supporting the potential of this IADL in early AD using technology. This promising early data including near‐significant trends (e.g., duration of tasks between PreAD and ProAD) will be investigated deeper as the study and data collection are on‐going. This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking RADAR‐AD (grant No 806999) and their associated partners.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.